Associations - Nerlynx (neratinib)

HR positive	HER2 Positive Breast Cancer	HR positive	HER2 Positive Breast Cancer	neratinib Sensitive: A1 - Approval neratinib Sensitive : A1	neratinib Sensitive: A1 - Approval neratinib Sensitive : A1
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	neratinib Sensitive: A1 - Approval neratinib Sensitive : A1	neratinib Sensitive: A1 - Approval neratinib Sensitive : A1
HER-2 overexpression	Hormone Receptor Positive Breast Cancer	HER-2 overexpression	Hormone Receptor Positive Breast Cancer	neratinib Sensitive: A1 - Approval neratinib Sensitive : A1	neratinib Sensitive: A1 - Approval neratinib Sensitive : A1
HER-2 amplification	Hormone Receptor Positive Breast Cancer	HER-2 amplification	Hormone Receptor Positive Breast Cancer	neratinib Sensitive: A1 - Approval neratinib Sensitive : A1	neratinib Sensitive: A1 - Approval neratinib Sensitive : A1
HER-2 amplification	HER2 Positive Breast Cancer	HER-2 amplification	HER2 Positive Breast Cancer	neratinib Sensitive: A1 - Approval neratinib Sensitive : A1	neratinib Sensitive: A1 - Approval neratinib Sensitive : A1
HER-2 overexpression	HER2 Positive Breast Cancer	HER-2 overexpression	HER2 Positive Breast Cancer	neratinib Sensitive: A1 - Approval neratinib Sensitive : A1	neratinib Sensitive: A1 - Approval neratinib Sensitive : A1
ER positive	HER2 Positive Breast Cancer	ER positive	HER2 Positive Breast Cancer	neratinib Sensitive: A2 - Guideline neratinib Sensitive : A2	neratinib Sensitive: A2 - Guideline neratinib Sensitive : A2
HR positive	HER2 Positive Breast Cancer	HR positive	HER2 Positive Breast Cancer	trastuzumab + neratinib Sensitive: B - Late Trials trastuzumab + neratinib Sensitive : B	trastuzumab + neratinib Sensitive: B - Late Trials trastuzumab + neratinib Sensitive : B
HER-2 overexpression	Breast Cancer	HER-2 overexpression	Breast Cancer	neratinib Sensitive: B - Late Trials neratinib Sensitive : B	neratinib Sensitive: B - Late Trials neratinib Sensitive : B
PIK3CA mutation	HER2 Positive Breast Cancer	PIK3CA mutation	HER2 Positive Breast Cancer	neratinib Resistant: B - Late Trials neratinib Resistant : B	neratinib Resistant: B - Late Trials neratinib Resistant : B
HER-2 amplification	Breast Cancer	HER-2 amplification	Breast Cancer	neratinib Sensitive: C1 - Off-label neratinib Sensitive : C1	neratinib Sensitive: C1 - Off-label neratinib Sensitive : C1
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	neratinib Sensitive: C1 - Off-label neratinib Sensitive : C1	neratinib Sensitive: C1 - Off-label neratinib Sensitive : C1
HER-2 positive	Solid Tumor	HER-2 positive	Solid Tumor	neratinib Resistant: C1 - Off-label neratinib Resistant : C1	neratinib Resistant: C1 - Off-label neratinib Resistant : C1
HER-2 positive	Biliary Tract Cancer	HER-2 positive	Biliary Tract Cancer	neratinib Sensitive: C1 - Off-label neratinib Sensitive : C1	neratinib Sensitive: C1 - Off-label neratinib Sensitive : C1
HR positive	Hormone Receptor Positive Breast Cancer	HR positive	Hormone Receptor Positive Breast Cancer	trastuzumab + neratinib Sensitive: C2 – Inclusion Criteria trastuzumab + neratinib Sensitive : C2	trastuzumab + neratinib Sensitive: C2 – Inclusion Criteria trastuzumab + neratinib Sensitive : C2
HER-2 mutation	Hormone Receptor Positive Breast Cancer	HER-2 mutation	Hormone Receptor Positive Breast Cancer	trastuzumab + neratinib Sensitive: C2 – Inclusion Criteria trastuzumab + neratinib Sensitive : C2	trastuzumab + neratinib Sensitive: C2 – Inclusion Criteria trastuzumab + neratinib Sensitive : C2
EGFR exon 18 mutation	Non Small Cell Lung Cancer	EGFR exon 18 mutation	Non Small Cell Lung Cancer	neratinib Sensitive: C2 – Inclusion Criteria neratinib Sensitive : C2	neratinib Sensitive: C2 – Inclusion Criteria neratinib Sensitive : C2
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	neratinib + ado-trastuzumab emtansine Sensitive: C2 – Inclusion Criteria neratinib + ado-trastuzumab emtansine Sensitive : C2	neratinib + ado-trastuzumab emtansine Sensitive: C2 – Inclusion Criteria neratinib + ado-trastuzumab emtansine Sensitive : C2
HER-2 mutation	Cervical Cancer	HER-2 mutation	Cervical Cancer	neratinib Sensitive: C2 – Inclusion Criteria neratinib Sensitive : C2	neratinib Sensitive: C2 – Inclusion Criteria neratinib Sensitive : C2
HER-2 amplification	HER2 Positive Breast Cancer	HER-2 amplification	HER2 Positive Breast Cancer	neratinib + ado-trastuzumab emtansine Sensitive: C2 – Inclusion Criteria neratinib + ado-trastuzumab emtansine Sensitive : C2	neratinib + ado-trastuzumab emtansine Sensitive: C2 – Inclusion Criteria neratinib + ado-trastuzumab emtansine Sensitive : C2
HER-2 D769H	HER2 Negative Breast Cancer	HER-2 D769H	HER2 Negative Breast Cancer	neratinib Sensitive: C2 – Inclusion Criteria neratinib Sensitive : C2	neratinib Sensitive: C2 – Inclusion Criteria neratinib Sensitive : C2
HER-2 D769Y	HER2 Negative Breast Cancer	HER-2 D769Y	HER2 Negative Breast Cancer	neratinib Sensitive: C2 – Inclusion Criteria neratinib Sensitive : C2	neratinib Sensitive: C2 – Inclusion Criteria neratinib Sensitive : C2
HER-2 L755S	HER2 Negative Breast Cancer	HER-2 L755S	HER2 Negative Breast Cancer	neratinib Sensitive: C2 – Inclusion Criteria neratinib Sensitive : C2	neratinib Sensitive: C2 – Inclusion Criteria neratinib Sensitive : C2
HER-2 R896C	HER2 Negative Breast Cancer	HER-2 R896C	HER2 Negative Breast Cancer	neratinib Sensitive: C2 – Inclusion Criteria neratinib Sensitive : C2	neratinib Sensitive: C2 – Inclusion Criteria neratinib Sensitive : C2
HER-2 V777L	HER2 Negative Breast Cancer	HER-2 V777L	HER2 Negative Breast Cancer	neratinib Sensitive: C2 – Inclusion Criteria neratinib Sensitive : C2	neratinib Sensitive: C2 – Inclusion Criteria neratinib Sensitive : C2
HER-2 V842I	HER2 Negative Breast Cancer	HER-2 V842I	HER2 Negative Breast Cancer	neratinib Sensitive: C2 – Inclusion Criteria neratinib Sensitive : C2	neratinib Sensitive: C2 – Inclusion Criteria neratinib Sensitive : C2
HER-2 mutation	Breast Cancer	HER-2 mutation	Breast Cancer	neratinib Sensitive: C2 – Inclusion Criteria neratinib Sensitive : C2	neratinib Sensitive: C2 – Inclusion Criteria neratinib Sensitive : C2
EGFR G719X	Non Small Cell Lung Cancer	EGFR G719X	Non Small Cell Lung Cancer	neratinib Sensitive: C2 – Inclusion Criteria neratinib Sensitive : C2	neratinib Sensitive: C2 – Inclusion Criteria neratinib Sensitive : C2
HER-2 mutation	Non Small Cell Lung Cancer	HER-2 mutation	Non Small Cell Lung Cancer	trastuzumab + neratinib Sensitive: C3 – Early Trials trastuzumab + neratinib Sensitive : C3	trastuzumab + neratinib Sensitive: C3 – Early Trials trastuzumab + neratinib Sensitive : C3
HER-2 mutation	Non Small Cell Lung Cancer	HER-2 mutation	Non Small Cell Lung Cancer	neratinib + temsirolimus Sensitive: C3 – Early Trials neratinib + temsirolimus Sensitive : C3	neratinib + temsirolimus Sensitive: C3 – Early Trials neratinib + temsirolimus Sensitive : C3
HER-2 mutation	Biliary Tract Cancer	HER-2 mutation	Biliary Tract Cancer	neratinib Sensitive: C3 – Early Trials neratinib Sensitive : C3	neratinib Sensitive: C3 – Early Trials neratinib Sensitive : C3
HER-2 mutation	HER2 Positive Breast Cancer	HER-2 mutation	HER2 Positive Breast Cancer	neratinib Sensitive: C3 – Early Trials neratinib Sensitive : C3	neratinib Sensitive: C3 – Early Trials neratinib Sensitive : C3

Nerlynx (neratinib)

Associations
(102)

Associations
(102)

Nerlynx (neratinib)

Associations(102)

Associations(102)

Associations
(102)

Associations
(102)